First Reported Case of Pulmonary Arterial Hypertension Secondary to Tofacitinib Treatment for Undifferentiated Arthritis

Habib, Pauline; Podgorski, Mark; Adorini, Katrina; Brown, Martin M.; McLean, Amy; Tjeuw, Michael; Joshua, Fredrick; Ng, Benjamin K.

doi:10.1097/00124743-900000000-99135

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis only included very few patients of the work of Harigari [6]. Furthermore, one case of pulmonary hypertension has been described under tofacitinib [11].…”

Section: Discussionmentioning

confidence: 99%

Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient

Hamacher

2020

IJOPRS

View full text Add to dashboard Cite

A 68 years old rheumatoid arthritis patient received the janus kinase inhibitor baricitinib after a 2.5 years treatment with abatacept. Under abatacept she developed important cough, which was the reason to directly change to baricitinib. Within days cough was much aggravated and baricitinib treatment stopped after two weeks. The cough decreased, and six-week later baricitinib treatment was restarted. Within 14 days cough reappeared and novel exertional dyspnoea and hypoxaemia, aggravated with low exercise, and erythema at the face, neck, upper trunk, volar arms including wrists developed.Clinical findings, a novel restrictive lung function and gas diffusion impairment, and computer tomography were consistent with an acute pneumonitis due to baricitinib treatment. Baricitinib was stopped, and recovery was virtually complete within six weeks. We conclude that a very probable baricitinib pneumonitis occurred. To our knowledge, this is the first published case of this adverse effect in a rheumatoid arthritis patient.

show abstract

“…This analysis only included very few patients of the work of Harigari [6]. Furthermore, one case of pulmonary hypertension has been described under tofacitinib [11].…”

Section: Discussionmentioning

confidence: 99%

Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient

Hamacher

2020

IJOPRS

View full text Add to dashboard Cite

show abstract

First Reported Case of Pulmonary Arterial Hypertension Secondary to Tofacitinib Treatment for Undifferentiated Arthritis

Cited by 1 publication

References 0 publications

Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient

Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient

Contact Info

Product

Resources

About